The Role of PPAR Gamma in Systemic Sclerosis

Abstract

Fibrosis is recognized as an important feature of many chronic diseases, such as systemic sclerosis (SSc), an autoimmune disease of unknown etiology, characterized by immune dysregulation and vascular injury, followed by progressive fibrosis affecting the skin and multiple internal organs. SSc has a poor prognosis because no therapy has been shown to reverse or arrest the progression of fibrosis, representing a major unmet medical need. Recently, antifibrotic effects of PPARγ ligands have been studied in vitro and in vivo and some theories have emerged leading to new insights. Aberrant PPARγ function seems to be implicated in pathological fibrosis in the skin and lungs. This antifibrotic effect is mainly related to the inhibition of TGF-β/Smad signal transduction but other pathways can be involved. This review focused on recent studies that identified PPARγ as an important novel pathway with critical roles in regulating connective tissue homeostasis, with emphasis on skin and lung fibrosis and its role on systemic sclerosis.

Andrea Tavares Dantas 1, 2 and Michelly Cristiny Pereira 2 and Moacyr Jesus Barreto de Melo Rego 2 and Laurindo Ferreira da Rocha Jr. 1, 2 and Ivan da Rocha Pitta 3 and Claudia Diniz Lopes Marques 1 and Angela Luzia Branco Pinto Duarte 1 and Maira Galdino da Rocha Pitta 2

Academic Editor:Tom Hsun-Wei Huang

1, Serviço de Reumatologia do Hospital das Clinicas da Universidade Federal de Pernambuco (HC-UFPE), 50670-901 Recife, PE, Brazil
2, Laboratorio de Imunomodulação e Novas Abordagens Terapêuticas da Universidade Federal de Pernambuco (LINAT-UFPE), 50670-901 Recife, PE, Brazil
3, Laboratorio de Planejamento e Sintese de Farmacos da Universidade Federal de Pernambuco (LPSF-UFPE), 50670-901 Recife, PE, Brazil

Received 11 February 2015; Revised 23 April 2015; Accepted 23 April 2015; 6 May 2015

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Fibrosis is defined as an inappropriate repair by connective tissue characterized by excessive deposition of collagen and other extracellular matrix (ECM) components, promoting disruption of tissue homeostasis. It is recognized as an important feature of many chronic diseases, including myocardial infarction, glomerulosclerosis, idiopathic pulmonary fibrosis, liver cirrhosis, and systemic sclerosis (SSc) [1].

Fibroblasts are major effector cells in the development of fibrosis and an inappropriate fibroblast activation is the fundamental pathogenic alteration underlying pathologic fibrosis. A subgroup of resident fibroblasts, in response to transforming growth factor-β (TGF-β ) stimulation, transdifferentiate into myofibroblasts expressing high levels of α -smooth muscle actin (α -SMA) with a significant functional role in pathologic fibrosis. The myofibroblasts show accelerated synthesis of extracellular matrix proteins, are resistant to apoptosis, and have contractile properties. Furthermore, bone-marrow-derived mesenchymal progenitors such as fibrocytes and monocytes might traffic to damaged tissue and undergo in situ differentiation into activated fibroblasts and myofibroblasts. Nonfibroblastic cell lineages (such as epithelial or endothelial cells or adipocytes) can also differentiate into fibroblasts and myofibroblasts through a process called epithelial-mesenchymal transition (EMT) [2-4].

Regulation of these cellular transitions, collagen gene expression, and ECM accumulation is tightly controlled. Various chemokines/cytokines can induce cell migration and proliferation, as well as stimulation of cell-cell adhesion and collagen production, which is associated with the pathogenesis of fibrosis. TGF-β is considered the main regulator of physiologic fibrogenesis and pathological fibrosis, and it has emerged as an important therapeutic target in fibrotic diseases [5, 6].

Intracellular TGF-β signaling is primarily mediated via the canonical Smad pathway. Binding of TGF-β to type 2 TGF-β receptor recruits type 1 TGF-β receptors (TGF-β RI), forming a heterotetrameric structure that phosphorylates Smad2 and Smad3, which then binds to Smad4. The resulting Smad complex then translocates to the nucleus and binds to the Smad binding elements (SBE) in the gene promoter in order to regulate the transcription of target genes [7]. Smads regulate transcription of target genes by interacting with other transcription factors and by recruiting transcriptional coactivators or corepressors, such as CREB (cAMP response element binding protein) binding protein (CBP)/p300 [8].

Although the Smad pathway is the central intracellular mediator of signals from the TGF-β receptors, recent evidence indicates that alternative non-Smad pathways exist. This also mediates TGF-β responses, involving protein kinases (MAP kinases p38 and JNK, focal adhesion kinase FAK, and TGF-β activated kinase TAK1), lipid kinases such as PI3 kinase and its downstream target Akt, the calcium-dependent phosphatase calcineurin, and the nonreceptor tyrosine kinase c-Abl [9, 10].

Besides TGF-β , multiple cytokines, growth factors, and chemokines regulate collagen production, ECM accumulation, and mesenchymal cell function and are also expressed abnormally in fibrotic diseases. These mediators, such as connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), interleukin (IL)-4, IL-6, IL-13, and IL-8, interact with TGF-β and directly contribute to the pathogenesis of fibrosis and might also represent potential targets for antifibrotic therapy [11].

Although the diagnosis and pathophysiology of most fibrosing diseases have been better characterized over the past few years, there remains no effective therapy for this group of diseases. Systemic sclerosis is an autoimmune disease of unknown etiology, characterized by immune dysregulation and vascular injury, followed by progressive fibrosis affecting the skin and multiple internal organs, mainly the lung. The disease has a poor prognosis because no therapy has been shown to reverse or arrest the progression of fibrosis, representing a major unmet medical need.

Therapies initially targeted to inflammation proved to be ineffective. Thus, studies have focused on modulation of profibrotic molecules, targeting myofibroblast differentiation, recruitment, and activity as a potential antifibrotic treatment. Hence, the transcription factor peroxisome proliferator-activated receptor gamma (PPARγ ) appears to participate in controlling fibrogenesis by inhibiting the TGF-β pathway. Aberrant PPARγ function seems to be implicated in pathological fibrosis in the skin, lung, liver, heart, kidney, and pancreas. This review focused on recent studies that identified PPARγ as an important novel pathway with critical roles in regulating connective tissue homeostasis, with emphasis on skin and lung fibrosis and its role in systemic sclerosis.

2. Role of PPARγ in Fibrosis Signaling

PPARγ is a ligand-dependent nuclear receptor that belongs to the nuclear hormone receptor superfamily and regulates the expression of target genes. Some studies demonstrated the pivotal role of PPARγ in glucose homeostasis, lipid metabolism, and cell growth regulation and, posteriorly, in inflammation, innate immunity, and regulation of connective tissue biology [12]. It is now recognized that PPARγ modulates connective tissue synthesis and degradation, mesenchymal cell activation, transdifferentiation, and survival [13].

PPARγ is activated by natural and pharmacological agents. Endogenous ligands include 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), lysophosphatidic acid, and nitrolinoleic acid. PPARγ can also be activated by synthetic ligands including the thiazolidinediones (TZD) as well as oleanic acid derivatives known as triterpenoids (2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid (CDDO)) [14]. The TZDs are highly potent PPARγ agonists. They consist of rosiglitazone (RGZ), pioglitazone (PGZ), and troglitazone (TGZ) and were originally approved for the treatment of type 2 diabetes but their commercialization has been questioned in many countries mainly due to cardiovascular safety profile and increased risk of cancer and bone fractures [15-17].

In unstimulated cells, the PPARγ receptors are located in the cytoplasm as heterodimers complexed to their repressors. After ligation with its agonist, PPARγ heterodimerizes with retinoid X receptor (RXR) and coactivators such as p300 are recruited; this complex is translocated to the nucleus where it recognizes specific DNA sequence elements termed as peroxisome proliferator response element (PPRE) in promoters of target genes. PPARs regulate numerous genes through ligand-dependent transcriptional activation and repression [18, 19]. In the absence of ligands, the PPAR/RXR complex is bound to transcriptional corepressors and histone deacetylases, which prevents its binding to PPRE [13].

PPARγ express two isoforms: PPARγ 1, present in macrophages, colonic epithelial cells, endothelial cells, and vascular smooth muscle cells, and PPARγ 2, mainly expressed in adipose tissue associated with the regulation of adipogenesis. The expression level of PPARγ in a given cell or tissue determines the intensity and duration of the cellular response to endogenous or synthetic PPARγ ligands [6, 19].

Recent studies have established that PPARγ is a negative regulator of profibrotic signal-induced collagen synthesis and blunts fibrogenesis in a wide variety of organs. The antifibrotic effects of PPARγ ligands were studied in vitro and in vivo and some theories have emerged leading to new insights. Indeed, it is possible that they act through a variety of distinct mechanisms according to different cell types or type of agonist (natural or synthetic) [13, 20-27].

An inverse relationship between fibrosis and PPARγ expression/function was reported in multiple human fibrosing disorders as well as in animal models of fibrosis. Under physiologic conditions, PPARγ shows a low level of constitutive activation, driven by natural ligands controlling fibrotic responses. Prolonged or recurrent fibrogenic stimulation decreases the expression of PPARγ , inhibiting cellular responsiveness to natural endogenous PPARγ ligands. In multiple organ-specific human fibrotic diseases, fibrosis is preceded by reduced tissue PPARγ levels, suggesting a causal role for reduced PPARγ expression or activity in the development or progression of fibrosis [13]. It is not clear in these conditions whether fibrosis is the cause of reduced PPARγ or whether reduced PPARγ causes fibrosis [6].

Some cytokines and chemokines are recognized as regulators of PPARγ expression. Cytokines implicated in fibrosis generally suppress PPARγ expression in mesenchymal effector cells. As an example, TGF-β seems to reduce PPARγ expression in fibroblasts and hepatic stellate cells, although it stimulates PPARγ expression in monocytes and macrophages [13]. Other inhibitors of PPARγ expression include CTGF, IL-13, Wnt, leptin, lysophosphatidic acid (LPA), and hypoxia [28, 29].

On the contrary, adiponectin, which is regulated itself by PPARγ , enhances the expression of PPARγ in the liver and adipose tissue [30, 31]. Some molecules (L-carnitine, eplerenone, statins, and irbesartan) were studied as potential antifibrotic agents because of their effect on increasing PPARγ expression [32-35] (Figure 1).

Figure 1: Effects of different molecules on PPARγ expression.

[figure omitted; refer to PDF]

The molecular pathways underlying the antifibrotic effects of PPARγ are not completely defined. One of the proposed mechanisms is the antagonistic relationship between PPARγ and TGF-β signaling in fibrosis. As previously discussed, TGF-β promotes myofibroblasts differentiation from fibroblasts. In contrast, PPARγ ligands induce adipogenic differentiation of skin fibroblasts [21]. TGF-β negatively regulates both the expression and function of PPARγ , thereby desensitizing fibroblasts to PPARγ ligands. On the other hand, PPARγ ligands can directly disrupt TGF-β signal transduction and suppress TGF-β production [13, 21].

Activation of PPARγ by either naturally occurring or synthetic ligands inhibits the induction of profibrotic responses induced by TGF-β in fibroblasts. While the effects of PPARγ ligands (15d-PGJ2 and troglitazone) on collagen expression were only modest in unstimulated skin fibroblasts, these ligands significantly prevented collagen synthesis and expression in TGF-β -stimulated fibroblasts [21, 25-27]. PPARγ agonists (troglitazone, 15d-PGJ2, and CDDO) also prevented α -SMA expression induced by TGF-β in skin fibroblasts [25, 27]. In hepatic stellate cells, skin fibroblasts, and aortic muscle cells, PPARγ ligands suppressed CTGF expression induced by TGF-β 1 [36, 37].

In normal fibroblasts, PPARγ ligands can inhibit profibrotic signaling triggered by TGF-β and can interfere with downstream signal transduction. Blockage of the canonical Smad signaling pathway was demonstrated by some authors [26, 27, 38]. In hepatic stellate cells, PPARγ ligands prevented Smad3 phosphorylation [38]. In contrast, in the TGF-β -mediated fibroblast activation, PPARγ agonists did not prevent Smad2/3 phosphorylation or nuclear accumulation, but, instead, prevented recruitment of the coactivator p300 to the transcriptional complex [39]. In cultures of explanted normal fibroblasts, the PPARγ agonist CDDO prevented fibrogenic responses induced by TGF-β . Such effects occurred via disruption of Smad-dependent transcription, but without preventing Smad2/3 activation, and were also associated with inhibition of Akt activation [27].

In contrast, in dermal fibroblasts, rosiglitazone treatment did not attenuate expression of phosphorylated Smad2, suggesting that PPARγ ligands can abrogate TGF-β -induced responses independent of Smad activation [21, 25, 40]. For example, rosiglitazone reduced the induction of Egr-1, an early immediate transcription factor of TGF-β signaling [41]. Studies also implicate upregulation of the tumor suppressor phosphatase and tensin homolog (PTEN) as responsible for the inhibition of profibrotic effector functions by PPARγ . In vitro studies showed that PTEN inhibits fibroblast-myofibroblast differentiation and expression of α -SMA and collagen in human and mouse lung fibroblasts [42]. Accordingly, 15d-PGJ2 inhibited transcription of the TGF-β 1 gene via PTEN upregulation in mouse fibroblasts [43].

In mesangial cells, PPARγ ligands (15d-PGJ2, troglitazone, and ciglitazone) stimulated the expression of hepatocyte growth factor (HGF), an endogenous antifibrotic agent. HGF induces the Smad transcriptional corepressor TG-interacting factor (TGIF) thus mediating autocrine suppression of TGF-β -induced fibrogenic responses [44, 45].

Contrary to the mentioned findings, some studies suggested that antifibrotic effects of PPARγ ligands could not be related to PPARγ activation [46-49]. Ferguson et al. demonstrated that CDDO inhibited α -SMA expression by a PPARγ -independent mechanism, promoting dysregulation of acetylation of the TGF-β gene transcription coactivator CBP/p300 [48]. Similarly, Kulkarni et al. showed that PPARγ ligands inhibited TGFβ -induced Akt phosphorylation and this effect was not restored by PPARγ antagonist [49]. Figure 2 illustrates some effects of PPARγ in TGFβ signaling pathway.

Figure 2: Smad and non-Smad signaling TGF-β pathways and potential effects of PPARγ ligands. Binding of TGF-β to type 2 TGF-β receptor (TGF-β RII) recruits type 1 TGF-β receptors (TGF-β RI), forming a heterotetrameric structure that phosphorylates Smad2 and Smad3, which then binds to Smad4. Smad complex then translocates to the nucleus, where it interacts with various transcription factors to regulate the transcription of target genes (COL1A1, COL1A2, ASMA, CTGF). After TGF-β binding, TGF-β RII recruits a TGF-β RI and activates it by phosphorylation. Nonclassic pathways are also illustrated. PPARγ ligands can block TGF-β signaling by blocking Smad and non-Smad pathways.

[figure omitted; refer to PDF]

These data argue that PPARγ agonists have a role in limiting fibrosis, in addition to their already known anti-inflammatory and immunomodulatory effects. Tables 1 and 2 summarize in vitro and in vivo studies of antifibrotic effects of PPARγ agonists. This antifibrotic effect is mainly related to the inhibition of TGF-β /Smad signal transduction but other pathways may be involved. This knowledge has stimulated the development of further studies examining PPARγ role in fibrotic diseases and the potential therapeutic use of their ligands.

Table 1: In vitro studies of antifibrotic effects of PPARγ agonists.

Cell type	PPARg Ligand	Effects	References
Healthy human lung fibroblast	15d-PGJ2, CGZ and RGZ	[arrow down] TGF-β -induced myofibroblast differentiation[arrow down] TGF-β -induced type I collagen protein production	[40]
Normal lung fibroblasts and fibroblastsisolated from patients with IIP human fetal lung fibroblast (IMR-90) cells	CGZ and TGZ	[arrow down] Proliferation of human lung fibroblasts[arrow down] Proliferative responses of undifferentiated Fibroblasts and myofibroblasts to PDGF Inhibited TGF-β 1-induced myofibroblast differentiation	[47]
MRC-5 cells derived from human lung fibroblasts	PGZ	[arrow down] TGFβ -mediated increase in procollagen I and CTGF expression	[60]
RGZ	[arrow down] Lung fibroblast migration and proliferation [arrow down] Myofibroblast transdifferentiation	[56]
Normal human lung fibroblast cell	15 d-PGJ2, RGZ and CDDO	[arrow down] TGF-β -stimulated differentiation of fibroblasts to myofibroblasts[arrow down] TGF-β -induced fibronectin expression	[48]
A549 humanalveolar cell line	RGZ and CGZ	[arrow down] Profibrotic changes (elevation of N-cadherin, CTGF and collagen I) in alveolar epithelial cells	[59]
Primary lung human fibroblastsLung fibroblasts from IIP patients	CDDO and 15d-PGJ2	[arrow down] TGFβ -induced phosphorylation of Akt[arrow down] myofibroblast differentiation	[49]
SSc lung fibroblasts	RGZ	[arrow up] MMP-1 expression[arrow down] Collagen type I expression in white patients[arrow down] CTGF and α -SMA expression	[53]
Primary cultures of human dermalfibroblasts	15d-PGJ2 and TGZ	[arrow up] PPARγ nuclear levels in skin fibroblasts[arrow down] type I collagen synthesis and expression by TGFβ -stimulated fibroblasts[arrow down] α -SMA expression by TGFβ -stimulated fibroblasts	[25]
TGZ	[arrow down] TGFβ 1, type I collagen and fibronectin expression and secretion	[67]
Human foreskin fibroblasts	15d-PGJ2 and TGZ	[arrow down] Collagen synthesis and of COL1A2 promoter activity induced by TGF-β [arrow down] Smad3-dependent transcriptional responses without blocking Smad activation[arrow down] TGFβ -induced interaction of p300 with Smad3[arrow down] Recruitment of p300 to the DNA-bound transcriptional complex	[39]
Healthy and scleroderma fibroblasts	RGZ	[arrow down] α -SMA, type I collagen and CTGF protein expression in dcSSc fibroblasts [arrow up] PPARγ expression	[79]
Ajulemic acid	[arrow down] Supernatant levels of procollagen type I propeptide and TGFb	[69]
Human scleroderma fibroblasts	RGZ	Reduced CXCL10 secretion induced by IFNγ e TNFα	[86]
PGZ and RGZ	[arrow down] Cell proliferation and cell viabilityIncreased apoptosis	[80]
CDDO	[arrow down] Cellular and secreted type I collagen levels[arrow down] COL1A1 and COL1A2 mRNA expression	[27]
Explanted normal human skinFibroblasts	CDDO	[arrow down] COL1A2 and aSMA expression induced by TGFb	[27]
Organotypic human skin raft model (epidermal keratinocytes and dermal fibroblasts)	CDDO	[arrow down] COL1A1, COL1A2, and α -SMA expression in fibroblasts	[27]
Human A540 epithelial cells	CDDO	[arrow down] TGF-β -induced epithelial-mesenchymal transition	[27]

CGZ = ciglitazone, RGZ = rosiglitazone, TGF-β = transforming growth factor-β , TGZ = troglitazone, IIP = idiopathic interstitial pneumonia, PDGF = platelet-derived growth factor, PGZ = pioglitazone, CTGF = connective tissue growth factor, CDDO = 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid, SSc = systemic sclerosis, MMP-1 = matrix metalloproteinase-1, dSSc = diffuse systemic sclerosis.

Table 2: In vivo studies of antifibrotic effects of PPARγ agonists.

Animal model	PPARγ ligand	Effects	Reference
Bleomycin-induced model of lung fibrosis	15d-PGJ2 and RGZ	[arrow down] Histological evidence of lung fibrosis	[61]
TGZ	[arrow down] Hydroxyproline and collagen deposition in lung tissue Ameliorated histopathological changes	[47]
PGZ	[arrow down] Hydroxyproline content in lung tissue Ameliorated histopathological changes	[60]
RGZ	Prevented onset of fibrotic radiological changes	[63]
RGZ	[arrow down] Hydroxyproline content in lung tissue[arrow down] Lung TGF-β 1 concentrationAmeliorated histopathological changes	[62]
Bleomycin-induced model of skin fibrosis	RGZ	Attenuated severity of dermal fibrosis and local collagen deposition[arrow down] Tissue accumulation of myofibroblasts[arrow down] Levels of TGF-β levels in lesional skin	[41]
Ajulemic acid	Prevented development of skin fibrosis[arrow down] Skin thickness dermal[arrow down] Hydroxyproline content[arrow down] Myofibroblasts number	[69]
CDDO	[arrow down] Collagen deposition and dermal thickness[arrow down] α -SMA and TGFβ 1 expression	[27]
Constitutively active TGFβ receptor type I mouse model (AdTGFbRI)	Ajulemic acid	Prevented development of skin fibrosis[arrow down] Skin thickness dermal[arrow down] Hydroxyproline content[arrow down] Myofibroblasts number	[69]

RGZ = rosiglitazone, TGZ = troglitazone, PGZ = pioglitazone, CDDO = 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid, TGF-β = transforming growth factor-β , α -SMA = α -smooth muscle actin.

3. PPARγ and Lung Fibrosis

Lung fibrosis occurs in a wide variety of illnesses, including systemic disorders, as systemic sclerosis, as well as primary lung disease, such as idiopathic interstitial pneumonia (IIP). Fibrotic remodeling of lung tissue is also an important feature of other lung diseases, including sarcoidosis, asthma, and chronic obstructive pulmonary disease. In general, it is characterized by inflammatory cell infiltration and alveolar epithelial cell injury with failure of alveolar reepithelialization, followed by recruitment and persistence of fibroblasts that differentiate into myofibroblasts. The excessive collagen and extracellular matrix production results in distortion of the lung architecture and consequently decreased gas exchange and reduced pulmonary compliance [50, 51].

Many types of lung cells express PPARγ , including fibroblasts, T lymphocytes, ciliated airway epithelial cells, alveolar type II pneumocytes, alveolar macrophages, and airway smooth muscle cells [52]. Reduced PPARγ expression was demonstrated in lung fibroblasts from patients with SSc [22, 53] and in alveolar macrophages of patients with sarcoidosis [54] and pulmonary alveolar proteinosis [55], suggesting that insufficient PPARγ activity may contribute to ongoing dysregulated inflammation and fibrosis.

PPARγ ligands have negative regulatory effects on human lung fibroblasts, by inhibiting proliferation and migration of healthy or IIP fibroblasts and by inhibiting proliferative responses of undifferentiated fibroblasts and myofibroblasts to mitogenic growth factors, as PDGF [47, 56]. Furthermore, PPARγ agonists inhibited the human lung fibroblast transdifferentiation mediated by TGF-β to the myofibroblast phenotype [40, 47, 48, 56] and significantly reduced expression of fibronectin [48] and type I collagen TGF-β -stimulated [40, 47].

TGF-β is a potent stimulus for induction of pulmonary fibrosis in vivo [57]. Wei et al. demonstrated that normal lung fibroblasts stimulated with TGF-β showed a decrease in PPARγ expression [22]. In another experiment, primary lung fibroblasts showed a small and not significant increase, followed by an expressive downregulation of PPARγ expression after exposure to TGF-β , beginning after an hour and persisting for at least 48 hours. This effect was reduced in Smad3-deficient lung fibroblasts, suggesting that TGF-β 1 modulates PPARγ expression, in part, via Smad3 signaling. Additionally, the inhibition of transcriptional ability of PPARγ by TGF-β 1 was overcome by overexpression of PPARγ [24].

Other mechanisms are also proposed to explain PPARγ agonists action. Activation of ERK-MAPK pathway by TGF-β plays an important role in fibrosis by regulating myofibroblast transdifferentiation, cell proliferation, and survival, as well as ECM synthesis [58]. In lung fibroblasts, RGZ showed an antifibrotic effect by decreasing ERK phosphorylation induced by PDGF and TGF-β 1 [56].

Recent studies provide evidence that alveolar epithelial cells (AEC) can undergo a TGF-β 1-induced epithelial-mesenchymal transition (EMT), acquiring a fibroblast-like phenotype and possibly contributing to lung fibrosis. Phenotypic markers associated with EMT include the diminished expression of E-cadherin, a cell anchoring protein expressed specifically by epithelial cells, and an elevated expression of N-cadherin, normally present at relatively high levels in fibroblasts. Tan et al. demonstrated that RGZ and CGZ inhibited the elevation of markers of profibrotic phenotype (N-cadherin, CTGF, and collagen I) in TGF-β 1-stimulated A549 cells, a model of AEC type II [59].

Studies with animal models found that the PPARγ agonists troglitazone [47], pioglitazone [60], and rosiglitazone [61, 62] were able to inhibit lung fibrosis bleomycin induced. This inhibition was observed either before or even after bleomycin administration. The initial period of postinflammatory fibrosis could correspond to the period in which patients are likely to present symptoms [47, 60]. More recently, using microcomputed tomography to evaluate radiological changes in the murine model of lung fibrosis, two authors demonstrated that the treatment of bleomycin-instilled mice with RGZ prevented the development of [63] or improved [64] typical features of lung fibrosis, like ground glass opacity and consolidation.

In conclusion, there are some evidences that PPARγ agonists have antifibrotic effects on human lung fibroblasts, as demonstrated by the attenuation of bleomycin-induced lung injury and downregulation of TGF-β 1-mediated collagen deposition in fibrotic lung tissues (Figure 3).

Figure 3: Effects of PPARγ ligands in fibrotic diseases.

[figure omitted; refer to PDF]

4. PPARγ and Skin Fibrosis

Wound repair is a very complex and dynamic process, involving the interactions of multiple cell types and growth factors, cytokines, and soluble mediators. Normal cutaneous tissue repair involves an initial inflammatory phase, characterized by migration of inflammatory cells to the injured site, followed by a fibroproliferative phase, with synthesis and deposition of granulation tissue and neovascularization. Finally, the resolution phase is characterized by replacement of damaged and granulation tissue by newly synthesized fibrous matrix protein collagens. In response to tissue injury, myofibroblasts repopulate the wound and synthesize and remodel new ECM. Dysregulation of this process could result in chronic wounds or fibrosis [65, 66].

It is suggested that PPARγ may in part be responsible for initiating endogenous mechanisms of wound repair and the activation of PPARγ by its natural ligands controls fibrotic responses. Normal dermal fibroblasts constitutively express low levels of PPARγ , distributed in both nucleus and cytoplasm [21, 25, 67]. Kapoor et al. demonstrated that PPARγ is upregulated during the resolution phase of normal wound healing [68]. Besides, PGJ2 physiologically increases and there is an upregulation of PPARγ expression, leading to blocking of fibroblast activation and collagen neosynthesis [6, 68]. Migration of dermal fibroblasts plays a critical role in both normal wound healing and pathological fibrogenesis. Treatment with rosiglitazone abrogated stimulation of fibroblast migration and wound closure elicited by TGF-β [41].

In TGF-β -stimulated dermal fibroblasts, there was a significant time-dependent decrease in PPARγ expression and a similar inhibition of matrix metalloproteinase- (MMP-) 1 and Smad3. At the same time, there was an increase in the expression of fibrosis-related genes such as ASMA, SERPINE1, CTGF, and COMP1 [22]. In addition, it was demonstrated in vivo a decline in cutaneous PPARγ expression in a mouse model of bleomycin-induced skin fibrosis [41].

Skin fibrosis associated with progressive loss of PPARγ expression seems to be prevented or reduced by the administration of PPARγ ligands. In the model of bleomycin-induced skin fibrosis, treatment with PPARγ ligands (RGZ, CDDO) prevented the development of skin fibrosis and also reduced established fibrosis [21, 27]. Gonzalez et al., using ajulemic acid (AjA), a nonpsychoactive synthetic analogue of tetrahydrocannabinol that can bind to PPARγ , also demonstrated prevention of experimental bleomycin-induced dermal fibrosis and interruption of further progression of established fibrosis, but did not alter preexisting ECM accumulation [69].

In human dermal fibroblasts troglitazone reduced TGF-β 1 secretion [67] and administration of rosiglitazone substantially prevented the upregulation of TGF-β 1 [21]. PPARγ agonists also attenuated the upregulation of the fibrogenic genes COL1A1 and COL1A2 and reduced the number of α -SMA-positive fibroblastic cells [21]. An interesting finding was that the overexpression of PPARγ resulted in complete suppression of COL1A2 gene transcription stimulated by TGF-β , even in the absence of an activation ligand, and caused a sensitization of fibroblasts to the ligands. These observations suggest that the relatively low level of PPARγ expression in normal fibroblasts may be a limiting factor for negative regulation of TGF-β responses [25].

Ghosh et al. found that basal type I collagen gene expression was markedly elevated in mouse embryonic fibroblasts (MEFs) lacking PPARγ . The agonist 15d-PGJ2 failed to suppress the elevated levels of collagen in MEFs. At the same way, activity of the COL1A2 promoter was markedly elevated in PPARγ null MEFs and reconstitution of these cells with ectopic PPARγ resulted in downregulation of COL1A2 promoter activity. PPARγ null MEFs displayed elevated expression of type I TGF-β receptor (Tβ RI) and produced more TGF-β 1. Furthermore, PPARγ null MEFs showed Smad2/3 phosphorylation, with nuclear accumulation, even in the absence of stimulation by exogenous TGF-β . These results indicate that absence of PPARγ in MEFs is associated with constitutive upregulation of collagen gene expression and Smad activation, at least in part, due to autocrine TGF-β stimulation [70].

In animal models, PPARγ null skin fibroblasts showed an enhanced responsiveness to tissue injury, as shown by increased rate of dermal wound closure, concomitant with increased collagen deposition, greater expression of α -SMA, CTGF, and proliferating cell nuclear antigen (PCNA), a marker of cell proliferation. They also showed elevated phosphorylation of Smad3, Akt, and ERK. Conversely, loss of PPARγ expression by itself was not sufficient to promote skin fibrosis, since PPARγ -deficient skin did not show significant alterations in skin thickness or matrix accumulation [71].

In line with these findings, Kapoor et al., using bleomycin-induced skin fibrosis in PPARγ knockout mice, showed enhanced susceptibility to skin fibrosis as demonstrated by enhanced dermal thickness, higher scores for collagen content, and greater expression of α -SMA. PPARγ -deficient mice also showed elevated Smad3 phosphorylation, indicating a potentiation of the profibrotic TGFβ 1/Smad signaling pathway in the absence of PPARγ . TGF-β 1-stimulated dermal fibroblasts isolated from PPARγ -KO mice had an increase in expression of α -SMA and type I collagen [72]. Taken together, these findings suggest that PPARγ normally suppresses fibrogenesis in vivo and that loss of PPARγ expression in skin results in elevated profibrotic signaling [72, 73].

These data indicate that PPARγ plays an important role in suppressing the skin fibrogenic response by antagonizing TGF-β signaling in physiological conditions and highlight the potential ability of PPARγ agonists to inhibit abnormal synthesis and tissue accumulation of collagen in fibrotic diseases (Figure 3).

5. PPARγ and Systemic Sclerosis

Systemic sclerosis is a clinically heterogeneous disease, known as the most severe connective tissue disorder, and associated with a high mortality risk. Patients with SSc may exhibit proliferative small artery and obliterative microvascular disease. There is also inflammation and fibrosis affecting the skin, oesophagus, respiratory tract, and other target organs. Loss of cutaneous elasticity and accompanying tightness followed by thickening and hardening of the skin (sclerosis) is almost always present and it has an important impact on quality of life. Skin involvement is a marker of disease activity and presents correlation with disease prognosis [74]. Pulmonary involvement is also common in patients with SSc and most often comprises fibrosis or interstitial lung disease and pulmonary vascular disease leading to pulmonary arterial hypertension (PAH). Currently, pulmonary manifestations are the leading cause of disease-related morbidity and mortality in patients with SSc [75].

The pathological events in SSc are complex and include impaired communication between endothelial cells, epithelial cells, and fibroblasts; lymphocyte activation; autoantibody production; inflammation; connective tissue fibrosis. These events result in an accumulation of constituents of the ECM, which replaces the normal tissue architecture, thus culminating in organ failure [76]. Scleroderma fibroblasts display an activated phenotype characterized by overproduction of collagen, secretion of profibrotic cytokines and chemokines, and expression of cell-surface integrin adhesion molecules and receptors for TGF-β , PDGF, and CCL2. Furthermore, SSc fibroblasts show increased expression of α -SMA and resistance to apoptosis [77, 78].

Reduced expression of PPARγ mRNA and protein was demonstrated in SSc skin biopsies, as well as in explanted skin fibroblasts [22, 69, 70, 79]. Although the cause underlying the PPARγ deficit in SSc and other fibrosing conditions is not yet known, multiple factors implicated in the pathogenesis of fibrosis, such as TGF-β , CTGF, and IL-13, potently inhibit PPARγ expression and function [3].

PPARγ expression shows an inverse relationship with enhanced TGF-β signaling in SSc lesional tissue. Microarray-based expression profiling of SSc skin biopsies showed an inverse correlation between PPARγ mRNA and levels of plasminogen activator inhibitor-1 (PAI-1), a TGF-β -regulated gene and marker of TGF-β activity [22].

Although fibroblasts from lesional SSc skin show reduced PPARγ expression, treatment with PPARγ ligands was able to increase the levels of the endogenous PPARγ ligand 15d-PGJ2 and the PPARγ expression [69, 79]. Furthermore, rosiglitazone attenuated the activated phenotype of scleroderma fibroblasts, by suppressing α -SMA, type I collagen, and CTGF protein expression and by reducing the ability of these fibroblasts to contract collagen matrix [79]. Other nonthiazolidinic PPARγ ligands, AjA and CDDO, also reduced collagen neosynthesis by scleroderma fibroblasts in vitro , an action that was reversed completely by cotreatment with a selective PPARγ antagonist [27, 69].

The expression of PPARγ is also reduced in lung fibroblasts from SSc patients [22, 53]. Treatment with RGZ resulted in significantly increased levels of PPARγ in SSc but not in normal lung fibroblasts. In addition, RGZ increased the production of MMP-1 and inhibited collagen type I, CTGF, and α -SMA expression [53]. Besides, RGZ or PGZ significantly reduced cell proliferation and viability and increased apoptosis in SSc fibroblasts, whereas they did not present a significant influence on healthy fibroblasts [80].

As mentioned above, the role of myofibroblasts as the principal mesenchymal cell responsible for the formation of fibrotic tissue is already well established in SSc and other fibrotic diseases. However, the origin of myofibroblasts is not completely understood. Recently, it was suggested that myofibroblasts in fibrotic skin could originate from adiponectin-positive intradermal progenitors via adipocyte-myofibroblast transition [81]. In line with this, development of dermal fibrosis is accompanied by progressive atrophy of the subcutaneous adipose layer and fibrous tissue replacement. An interesting finding is that PPARγ ligands induced adipogenic differentiation of mature dermal fibroblasts as well as preadipocytes, and this process was reversed by TGF-β [21].

SSc patients showed reduced serum levels and skin expression of adiponectin. An inverse correlation between serum adiponectin levels and skin fibrosis was also observed in these patients [23, 82, 83]. Adiponectin is a direct transcriptional target of PPARγ , whose levels directly reflect PPARγ activity, and it could mediate the antifibrotic effects of PPARγ [84, 85]. It was demonstrated that this adipokine suppressed the expression of type I collagen and α -SMA in normal and scleroderma fibroblasts and abrogated the stimulation of these responses elicited by TGF-β [85]. Thus, adiponectin levels might be a potential biomarker of the level of PPARγ expression and progression of fibrosis.

Rosiglitazone attenuated the CXCL10/IP-10 secretion in explanted SSc fibroblasts, suggesting other potential effects of PPARγ ligands in SSc apart from antifibrotic action [86]. CXCL10 has been implicated in SSc pathogenesis since increased serum levels and epidermis expression were demonstrated in SSc patients [87] in addition to an association with more severe clinical phenotype [88].

These studies demonstrated that PPARγ expression and activity are reduced in SSc. This impaired PPARγ expression resulting from its suppression by TGF-β and related cytokines might contribute to unregulated fibroblast activation and persistent fibrogenesis and represent an important advance in understanding the pathophysiology of SSc. Therefore, more studies are needed to evaluate the therapeutic potential of PPARγ ligands in SSc (Figure 3).

6. Conclusion

Fibrosis is a major medical problem, which can lead to progressive dysfunction of many organs and eventually the death of patients. Many aspects of its molecular mechanisms are still unclear. Currently, no effective antifibrotic treatment is available. There are many studies suggesting a key physiologic function of PPARγ signaling as an endogenous mechanism to prevent excessive fibrogenesis following injury. PPARγ is a negative regulator of profibrotic signal-induced collagen synthesis and reduces fibrogenesis in a wide variety of organs in experimental animal models of fibrosis. Activation of cellular PPARγ receptors using either synthetic or natural PPARγ ligands blocks the induction of profibrotic responses. Experimental studies in systemic sclerosis demonstrated an impaired PPARγ expression and function, supporting a potential pathogenic role of PPARγ in this disease. Thus the use of synthetic agonists to induce the activation of PPARγ signaling or to enhance defective PPARγ tissue expression might be investigated as novel therapeutical approaches to the treatment of fibrosis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] Y.-L. Deng, X.-Z. Xiong, N.-S. Cheng, "Organ fibrosis inhibited by blocking transforming growth factor-beta signaling via peroxisome proliferator-activated receptor gamma agonists," Hepatobiliary and Pancreatic Diseases International , vol. 11, no. 5, pp. 467-478, 2012.

[2] J. A. Varga, M. Trojanowska, "Fibrosis in systemic sclerosis," Rheumatic Disease Clinics of North America , vol. 34, no. 1, pp. 115-143, 2008.

[3] J. Wei, S. Bhattacharyya, W. G. Tourtellotte, J. Varga, "Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy," Autoimmunity Reviews , vol. 10, no. 5, pp. 267-275, 2011.

[4] R. T. Kendall, C. A. Feghali-Bostwick, "Fibroblasts in fibrosis: novel roles and mediators," Frontiers in Pharmacology , vol. 5, article 123, 2014.

[5] J. Rosenbloom, S. V. Castro, S. A. Jimenez, "Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies," Annals of Internal Medicine , vol. 152, no. 3, pp. 159-166, 2010.

[6] J. Wei, S. Bhattacharyya, J. Varga, "Peroxisome proliferator-activated receptor γ : innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis," Current Opinion in Rheumatology , vol. 22, no. 6, pp. 671-676, 2010.

[7] G. C. Blobe, W. P. Schiemann, H. F. Lodish, "Role of transforming growth factor β in human disease," The New England Journal of Medicine , vol. 342, no. 18, pp. 1350-1358, 2000.

[8] R. Derynck, Y. E. Zhang, "Smad-dependent and Smad-independent pathways in TGF-β family signalling," Nature , vol. 425, no. 6958, pp. 577-584, 2003.

[9] J. Varga, B. Pasche, "Transforming growth factor beta as a therapeutic target in systemic sclerosis," Nature reviews. Rheumatology , vol. 5, no. 4, pp. 200-206, 2009.

[10] S. Bhattacharyya, J. Wei, W. G. Tourtellotte, M. Hinchcliff, C. G. Gottardi, J. Varga, "Fibrosis in systemic sclerosis: common and unique pathobiology," Fibrogenesis and Tissue Repair , vol. 5, no. 1, article S18, 2012.

[11] T. A. Wynn, "Cellular and molecular mechanisms of fibrosis," Journal of Pathology , vol. 214, no. 2, pp. 199-210, 2008.

[12] M. Lehrke, M. A. Lazar, "The many faces of PPARgamma," Cell , vol. 123, no. 6, pp. 993-999, 2005.

[13] J. Wei, S. Bhattacharyya, M. Jain, J. Varga, "Regulation of matrix remodeling by peroxisome proliferator-activated receptor-γ : a novel link between metabolism and fibrogenesis," Open Rheumatology Journal , vol. 6, no. 1, pp. 103-115, 2012.

[14] H. F. Lakatos, T. H. Thatcher, R. M. Kottmann, T. M. Garcia, R. P. Phipps, P. J. Sime, "The role of PPARs in lung fibrosis," PPAR Research , vol. 2007, 2007.

[15] S. A. Brietzke, "Oral antihyperglycemic treatment options for type 2 diabetes mellitus," Medical Clinics of North America , vol. 99, no. 1, pp. 87-106, 2015.

[16] C. Bosetti, V. Rosato, D. Buniato, A. Zambon, C. La Vecchia, G. Corrao, "Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis," The Oncologist , vol. 18, no. 2, pp. 148-156, 2013.

[17] Z. Zhu, Y. Jiang, T. Ding, "Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials," Bone , vol. 68, pp. 115-123, 2014.

[18] E. M. Zardi, L. Navarini, G. Sambataro, P. Piccinni, F. M. Sambataro, C. Spina, A. Dobrina, "Hepatic PPARs: their role in liver physiology, fibrosis and treatment," Current Medicinal Chemistry , vol. 20, no. 27, pp. 3370-3396, 2013.

[19] L. F. da Rocha Junior, A. T. Dantas, Â. L. B. P. Duarte, M. J. B. de Melo Rego, I. D. R. Pitta, M. G. D. R. Pitta, "PPARγ agonists in adaptive immunity: what do immune disorders and their models have to tell us?," PPAR Research , vol. 2013, 2013.

[20] J. T. M. Tan, S. V. McLennan, W. W. Song, L. W.-Y. Lo, J. G. Bonner, P. F. Williams, S. M. Twigg, "Connective tissue growth factor inhibits adipocyte differentiation," American Journal of Physiology-Cell Physiology , vol. 295, no. 3, pp. C740-C751, 2008.

[21] M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, J. Varga, "Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ," American Journal of Pathology , vol. 174, no. 2, pp. 519-533, 2009.

[22] J. Wei, A. K. Ghosh, J. L. Sargent, K. Komura, M. Wu, Q.-Q. Huang, M. Jain, M. L. Whitfield, C. Feghali-Bostwick, J. Varga, "PPARγ downregulation by TGFß in in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis," PLoS ONE , vol. 5, no. 11, 2010.

[23] K. Lakota, J. Wei, M. Carns, M. Hinchcliff, J. Lee, M. L. Whitfield, S. Sodin-Semrl, J. Varga, "Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?," Arthritis Research and Therapy , vol. 14, no. 3, article R102, 2012.

[24] A. Ramirez, E. N. Ballard, J. Roman, "TGFβ 1 controls PPARγ expression, transcriptional potential, and activity, in part, through Smad3 signaling in murine lung fibroblasts," PPAR Research , vol. 2012, 2012.

[25] A. K. Ghosh, S. Bhattacharyya, G. Lakos, S.-J. Chen, Y. Mori, J. Varga, "Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor γ ," Arthritis & Rheumatism , vol. 50, no. 4, pp. 1305-1318, 2004.

[26] A. K. Ghosh, S. Bhattacharyya, J. Wei, S. Kim, Y. Barak, Y. Mori, J. Varga, "Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator," The FASEB Journal , vol. 23, no. 9, pp. 2968-2977, 2009.

[27] J. Wei, H. Zhu, K. Komura, G. Lord, M. Tomcik, W. Wang, S. Doniparthi, Z. Tamaki, M. Hinchcliff, J. H. W. Distler, J. Varga, "A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ -independent suppression of fibrotic responses," Annals of the Rheumatic Diseases , vol. 73, no. 2, pp. 446-454, 2014.

[28] X. Li, H. Kimura, K. Hirota, H. Sugimoto, N. Kimura, N. Takahashi, H. Fujii, H. Yoshida, "Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-γ in human proximal renal tubular cells," Nephrology Dialysis Transplantation , vol. 22, no. 4, pp. 1041-1051, 2007.

[29] S. E. Ross, N. Hemati, K. A. Longo, C. N. Bennett, P. C. Lucas, R. L. Erickson, O. A. MacDougald, "Inhibition of adipogenesis by Wnt signaling," Science , vol. 289, no. 5481, pp. 950-953, 2000.

[30] K. M. Ajuwon, M. E. Spurlock, "Adiponectin inhibits LPS-induced NF-κ B activation and IL-6 production and increases PPARγ 2 expression in adipocytes," American Journal of Physiology-Regulatory Integrative and Comparative Physiology , vol. 288, no. 5, pp. R1220-R1225, 2005.

[31] M. S. Shafiei, S. Shetty, P. E. Scherer, D. C. Rockey, "Adiponectin regulation of stellate cell activation via PPARγ -dependent and -independent mechanisms," The American Journal of Pathology , vol. 178, no. 6, pp. 2690-2699, 2011.

[32] Y.-W. Qin, P. Ye, J.-Q. He, L. Sheng, L.-Y. Wang, J. Du, "Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a Western-style diet by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels," Acta Pharmacologica Sinica , vol. 31, no. 10, pp. 1350-1358, 2010.

[33] M. Miana, N. de las Heras, C. Rodriguez, D. Sanz-Rosa, B. Martin-Fernandez, S. Mezzano, V. Lahera, J. Martinez-Gonzalez, V. Cachofeiro, "Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma(PPAR-γ )," Journal of Physiology and Pharmacology , vol. 62, no. 1, pp. 87-94, 2011.

[34] Z.-Z. Zhang, Q.-H. Shang, H.-Y. Jin, B. Song, G. Y. Oudit, L. Lu, T. Zhou, Y.-L. Xu, P.-J. Gao, D.-L. Zhu, J. M. Penninger, J.-C. Zhong, "Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice," Journal of Translational Medicine , vol. 11, no. 1, article 229, 2013.

[35] S. Zambrano, A. J. Blanca, M. V. Ruiz-Armenta, J. L. Miguel-Carrasco, M. Arevalo, A. Mate, C. M. Vazquez, "L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ ," American Journal of Hypertension , vol. 27, no. 3, pp. 460-470, 2014.

[36] K. Sun, Q. Wang, X.-H. Huang, "PPAR gamma inhibits growth of rat hepatic stellate cells and TGF betainduced connective tissue growth factor expression," Acta Pharmacologica Sinica , vol. 27, no. 6, pp. 715-723, 2006.

[37] G.-Y. Zhang, T. Cheng, M.-H. Zheng, C.-G. Yi, H. Pan, Z.-J. Li, X.-L. Chen, Q. Yu, L.-F. Jiang, F.-Y. Zhou, X.-Y. Li, J.-Q. Yang, T.-G. Chu, W.-Y. Gao, "Activation of peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β 1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro," Archives of Dermatological Research , vol. 301, no. 7, pp. 515-522, 2009.

[38] C. Zhao, W. Chen, L. Yang, L. Chen, S. A. Stimpson, A. M. Diehl, "PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells," Biochemical and Biophysical Research Communications , vol. 350, no. 2, pp. 385-391, 2006.

[39] M. Zhu, L. Flynt, S. Ghosh, M. Mellema, A. Banerjee, E. Williams, R. A. Panettieri Jr., S. A. Shore, "Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells," American Journal of Respiratory Cell and Molecular Biology , vol. 45, no. 1, pp. 111-119, 2011.

[40] H. A. Burgess, L. E. Daugherty, T. H. Thatcher, H. F. Lakatos, D. M. Ray, M. Redonnet, R. P. Phipps, P. J. Sime, "PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis," The American Journal of Physiology-Lung Cellular and Molecular Physiology , vol. 288, no. 6, pp. L1146-L1153, 2005.

[41] H.-F. Pan, X.-F. Zhao, H. Yuan, W.-H. Zhang, X.-P. Li, G.-H. Wang, G.-C. Wu, X.-W. Tang, W.-X. Li, L.-H. Li, J.-B. Feng, C.-S. Hu, D.-Q. Ye, "Decreased serum IL-22 levels in patients with systemic lupus erythematosus," Clinica Chimica Acta , vol. 401, no. 1-2, pp. 179-180, 2009.

[42] E. S. White, R. G. Atrasz, B. Hu, S. H. Phan, V. Stambolic, T. W. Mak, C. M. Hogaboam, K. R. Flaherty, F. J. Martinez, C. D. Kontos, G. B. Toews, "Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10)," American Journal of Respiratory and Critical Care Medicine , vol. 173, no. 1, pp. 112-121, 2006.

[43] S. J. Lee, E. K. Yang, S. G. Kim, "Peroxisome proliferator-activated receptor-γ and retinoic acid X receptor α represses the TGFβ 1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation," Molecular Pharmacology , vol. 70, no. 1, pp. 415-425, 2006.

[44] Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, Y. Liu, "Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-γ agonists," Journal of the American Society of Nephrology , vol. 17, no. 1, pp. 54-65, 2006.

[45] Y. Zhao, Y. Huang, J. He, C. Li, W. Deng, X. Ran, D. Wang, "Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma," Immunology Letters , vol. 157, no. 1-2, pp. 9-15, 2014.

[46] B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, M. Haneda, "Peroxisome proliferator-activated receptor-γ ligands inhibit TGF-β 1-induced fibronectin expression in glomerular mesangial cells," Diabetes , vol. 53, no. 1, pp. 200-208, 2004.

[47] J. E. Milam, V. G. Keshamouni, S. H. Phan, B. Hu, S. R. Gangireddy, C. M. Hogaboam, T. J. Standiford, V. J. Thannickal, R. C. Reddy, "PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis," American Journal of Physiology-Lung Cellular and Molecular Physiology , vol. 294, no. 5, pp. L891-L901, 2008.

[48] H. E. Ferguson, A. Kulkarni, G. M. Lehmann, T. M. Garcia-Bates, T. H. Thatcher, K. R. Huxlin, R. P. Phipps, P. J. Sime, "Electrophilic peroxisome proliferator-activated receptor-γ ligands have potent antifibrotic effects in human lung fibroblasts," American Journal of Respiratory Cell and Molecular Biology , vol. 41, no. 6, pp. 722-730, 2009.

[49] A. A. Kulkarni, T. H. Thatcher, K. C. Olsen, S. B. Maggirwar, R. P. Phipps, P. J. Sime, "PPAR-γ ligands repress TGFβ -induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis," PLoS ONE , vol. 6, no. 1, 2011.

[50] S. H. Phan, "The myofibroblast in pulmonary fibrosis," Chest , vol. 122, no. 6, supplement, pp. 286s-289s, 2002.

[51] E. B. Meltzer, P. W. Noble, "Idiopathic pulmonary fibrosis," Orphanet Journal of Rare Diseases , vol. 3, no. 1, article 8, 2008.

[52] T. H.-W. Huang, V. Razmovski-Naumovski, B. P. Kota, D. S.-H. Lin, B. D. Roufogalis, "The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases," Respiratory Research , vol. 6, article 102, 2005.

[53] G. S. Bogatkevich, K. B. Highland, T. Akter, R. M. Silver, "The PPARγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects," Pulmonary Medicine , vol. 2012, 2012.

[54] D. A. Culver, B. P. Barna, B. Raychaudhuri, T. L. Bonfield, S. Abraham, A. Malur, C. F. Farver, M. S. Kavuru, M. J. Thomassen, "Peroxisome proliferator-activated receptor γ activity is deficient in alveolar macrophages in pulmonary sarcoidosis," American Journal of Respiratory Cell and Molecular Biology , vol. 30, no. 1, pp. 1-5, 2004.

[55] T. L. Bonfield, C. F. Farver, B. P. Barna, A. Malur, S. Abraham, B. Raychaudhuri, M. S. Kavuru, M. J. Thomassen, "Peroxisome proliferator-activated receptor-γ is deficient in alveolar macrophages from patients with alveolar proteinosis," American Journal of Respiratory Cell and Molecular Biology , vol. 29, no. 6, pp. 677-682, 2003.

[56] Q. Lin, L.-P. Fang, W.-W. Zhou, X.-M. Liu, "Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts," Experimental Lung Research , vol. 36, no. 2, pp. 120-128, 2010.

[57] A. L. Tatler, G. Jenkins, "TGF-beta activation and lung fibrosis," Proceedings of the American Thoracic Society , vol. 9, no. 3, pp. 130-136, 2012.

[58] S. Nakerakanti, M. Trojanowska, "The role of TGF-β receptors in fibrosis," The Open Rheumatology Journal , vol. 6, no. 1, pp. 156-162, 2012.

[59] X. Tan, H. Dagher, C. A. Hutton, J. E. Bourke, "Effects of PPARγ ligands on TGF-β 1-induced epithelial-mesenchymal transition in alveolar epithelial cells," Respiratory Research , vol. 11, article 21, 2010.

[60] Y. Aoki, T. Maeno, K. Aoyagi, M. Ueno, F. Aoki, N. Aoki, J. Nakagawa, Y. Sando, Y. Shimizu, T. Suga, M. Arai, M. Kurabayashi, "Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis," Respiration , vol. 77, no. 3, pp. 311-319, 2009.

[61] T. Genovese, S. Cuzzocrea, R. Di Paola, E. Mazzon, C. Mastruzzo, P. Catalano, M. Sortino, N. Crimi, A. P. Caputi, C. Thiemermann, C. Vancheri, "Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury," European Respiratory Journal , vol. 25, no. 2, pp. 225-234, 2005.

[62] M. Samah, A. E.-R. El-Aidy, M. K. Tawfik, M. M. S. Ewais, "Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats," European Journal of Pharmacology , vol. 689, no. 1-3, pp. 186-193, 2012.

[63] G. Y. Jin, S. M. Bok, Y. M. Han, M. J. Chung, K.-H. Yoon, S. R. Kim, Y. C. Lee, "Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: assessed by micro-computed tomography and pathologic scores," European Journal of Radiology , vol. 81, no. 8, pp. 1901-1906, 2012.

[64] E. J. Choi, G. Y. Jin, S. M. Bok, Y. M. Han, Y. S. Lee, M. J. Jung, "Serial micro-CT assessment of the therapeutic effects of rosiglitazone in a bleomycin-induced lung fibrosis mouse model," Korean Journal of Radiology , vol. 15, no. 4, pp. 448-455, 2014.

[65] J. J. Tomasek, G. Gabbiani, B. Hinz, C. Chaponnier, R. A. Brown, "Myofibroblasts and mechano: regulation of connective tissue remodelling," Nature Reviews Molecular Cell Biology , vol. 3, no. 5, pp. 349-363, 2002.

[66] A. K. Ghosh, S. E. Quaggin, D. E. Vaughan, "Molecular basis of organ fibrosis: potential therapeutic approaches," Experimental Biology and Medicine , vol. 238, no. 5, pp. 461-481, 2013.

[67] G.-Y. Zhang, T. Cheng, M.-H. Zheng, C.-G. Yi, H. Pan, Z.-J. Li, X.-L. Chen, Q. Yu, L.-F. Jiang, F.-Y. Zhou, X.-Y. Li, J.-Q. Yang, T.-G. Chu, W.-Y. Gao, "Peroxisome proliferator-activated receptor-γ (PPAR-γ ) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts," Journal of Plastic, Reconstructive and Aesthetic Surgery , vol. 63, no. 7, pp. 1209-1216, 2010.

[68] M. Kapoor, F. Kojima, L. Yang, L. J. Crofford, "Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study," Prostaglandins Leukotrienes and Essential Fatty Acids , vol. 76, no. 2, pp. 103-112, 2007.

[69] E. G. Gonzalez, E. Selvi, E. Balistreri, A. Akhmetshina, K. Palumbo, S. Lorenzini, P. E. Lazzerini, C. Montilli, P. L. Capecchi, M. Lucattelli, C. Baldi, E. Gianchechi, M. Galeazzi, F. L. Pasini, J. H. W. Distler, "Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis," Annals of the Rheumatic Diseases , vol. 71, no. 9, pp. 1545-1551, 2012.

[70] A. K. Ghosh, J. Wei, M. Wu, J. Varga, "Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-γ ," Biochemical and Biophysical Research Communications , vol. 374, no. 2, pp. 231-236, 2008.

[71] X. Li, J. Mai, A. Virtue, Y. Yin, R. Gong, X. Sha, S. Gutchigian, A. Frisch, I. Hodge, X. Jiang, H. Wang, X.-F. Yang, "IL-35 is a novel responsive anti-inflammatory cytokine-a new system of categorizing anti-inflammatory cytokines," PLoS ONE , vol. 7, no. 3, 2012.

[72] M. Kapoor, M. McCann, S. Liu, K. Huh, C. P. Denton, D. J. Abraham, A. Leask, "Loss of peroxisome proliferator-activated receptor γ in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis," Arthritis and Rheumatism , vol. 60, no. 9, pp. 2822-2829, 2009.

[73] W. Sha, K. Thompson, J. South, M. Baron, A. Leask, "Loss of PPARγ expression by fibroblasts enhances dermal wound closure," Fibrogenesis and Tissue Repair , vol. 5, no. 1, article 5, 2012.

[74] T. Krieg, K. Takehara, "Skin disease: a cardinal feature of systemic sclerosis,", supplement 3 Rheumatology , vol. 48, pp. iii14-iii18, 2009.

[75] A. U. Wells, V. Steen, G. Valentini, "Pulmonary complications: one of the most challenging complications of systemic sclerosis,", supplement 3 Rheumatology , vol. 48, pp. iii40-iii44, 2009.

[76] D. J. Abraham, T. Krieg, J. Distler, O. Distler, "Overview of pathogenesis of systemic sclerosis,", supplement 3 Rheumatology , vol. 48, pp. iii3-iii7, 2009.

[77] S. Bhattacharyya, J. Wei, J. Varga, "Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities," Nature Reviews Rheumatology , vol. 8, no. 1, pp. 42-54, 2012.

[78] Y. Y. Ho, D. Lagares, A. M. Tager, M. Kapoor, "Fibrosis-a lethal component of systemic sclerosis," Nature Reviews Rheumatology , vol. 10, no. 7, pp. 390-402, 2014.

[79] X. Shi-Wen, M. Eastwood, R. J. Stratton, C. P. Denton, A. Leask, D. J. Abraham, "Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts," Rheumatology , vol. 49, no. 2, pp. 259-263, 2010.

[80] A. Antonelli, C. Ferri, S. M. Ferrari, M. Colaci, I. Ruffilli, M. Sebastiani, P. Fallahi, "Peroxisome proliferator-activated receptor gamma agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts," British Journal of Dermatology , vol. 168, no. 1, pp. 129-135, 2013.

[81] R. G. Marangoni, B. D. Korman, J. Wei, T. A. Wood, L. V. Graham, M. L. Whitfield, P. Scherer, W. Tourtellotte, J. Varga, "Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors," Arthritis & Rheumatology , vol. 67, no. 4, pp. 1062-1073, 2015.

[82] Y. Masui, Y. Asano, S. Shibata, S. Noda, N. Aozasa, K. Akamata, D. Yamada, Z. Tamaki, Y. Tada, M. Sugaya, S. Sato, T. Kadono, "Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis," Journal of the European Academy of Dermatology and Venereology , vol. 26, no. 3, pp. 354-360, 2012.

[83] H. Arakawa, M. Jinnin, F. C. Muchemwa, T. Makino, I. Kajihara, K. Makino, N. Honda, K. Sakai, S. Fukushima, H. Ihn, "Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients," Experimental Dermatology , vol. 20, no. 9, pp. 764-766, 2011.

[84] C. M. Kusminski, P. E. Scherer, "The road from discovery to clinic: adiponectin as a biomarker of metabolic status," Clinical Pharmacology & Therapeutics , vol. 86, no. 6, pp. 592-595, 2009.

[85] F. Fang, L. Liu, Y. Yang, Z. Tamaki, J. Wei, R. G. Marangoni, S. Bhattacharyya, R. S. Summer, B. Ye, J. Varga, "The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy," Arthritis Research and Therapy , vol. 14, article R229, 2012.

[86] A. Antonelli, S. M. Ferrari, P. Fallahi, E. Ghiri, C. Crescioli, P. Romagnani, P. Vitti, M. Serio, E. Ferrannini, "Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists," Cytokine , vol. 50, no. 3, pp. 260-267, 2010.

[87] B. J. Rabquer, P.-S. Tsou, Y. Hou, E. Thirunavukkarasu, G. K. Haines, A. J. Impens, K. Phillips, B. Kahaleh, J. R. Seibold, A. E. Koch, "Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis," Arthritis Research & Therapy , vol. 13, no. 1, article R18, 2011.

[88] A. Antonelli, C. Ferri, P. Fallahi, S. M. Ferrari, D. Giuggioli, M. Colaci, A. Manfredi, S. Frascerra, F. Franzoni, F. Galetta, E. Ferrannini, "CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis-a longitudinal study," Rheumatology , vol. 47, no. 1, pp. 45-49, 2008.